“Pharma poised for big win.” That was the headline in the Washington Post last week as the House passed a government funding bill that included unrelated policy regulating how employers contract with their pharmacy benefit manager (PBM). The Senate should reject policies in
Upcoming Events Events 10 Nov 10 Nov – 11 Nov Test 2021-11-10 01:00 AM – 2021-11-11 03:00 AM Online Event PCMA Spring Webinar Series 2020 The live webinar series is designed to highlight drug supply chain executives’ thoughts and strategies
PCMA pointed to a blog post written by CEO JC Scott, which said PBMs are “voluntarily paying dispensing fees for these drugs, which are not technically covered by Medicare and other insurance,” and “most PBMs are paying standard or Medicaid-level” fees.
JC Scott, the President & CEO of the Pharmaceutical Care Management Association (PCMA), which represents pharmacy benefit managers, said PBMs are “voluntarily paying dispensing fees for these drugs, which are not technically covered by Medicare and other insurance.”
Benefit managers will likely revise fees, but are looking for the government to provide more direction on what the fees should be, said JC Scott, chief executive of the Pharmaceutical Care Management Association, the trade group for pharmacy-benefit managers.
PCMA pointed to a blog post written by CEO JC Scott, which said PBMs are “voluntarily paying dispensing fees for these drugs, which are not technically covered by Medicare and other insurance,” and “most PBMs are paying standard or Medicaid-level” fees.
The Pharmaceutical Care Management Association, which represents the pharmacy middlemen that help decide how a drug will be covered by insurance, said in an email that its members are “stepping up to support the government’s efforts” to provide effective Covid-19 treatments and that they are “making voluntary payments to pharmacies in order to maintain appropriate access to the medications for patients.”
